Making it possible through our patient and user-centric focus.

We believe that dedication to our end users, both patients and clinicians, is the key to developing lasting technological and workflow improvements to healthcare. We strive for simplicity, robustness, and intuitiveness as foundational elements of all our imaging solutions in order to delight all who touch our technology.


Baule and McFee make history when they record the biomagnetic signature of the heart.

This shows previously unseen and information-rich cardiac activity in a subject without any contact or energization required—a feat previously reserved for Science Fiction TV and Movies. The discovery is one of many brand-new clinical insights using the body's own energy as an indicator of health. Baule and McFee's novel insights blossom into the field of biomagnetism.


The United States Food and Drug Administration (FDA) authorizes marketing of the first commercial MCG system utilizing SQUID technology in the United States.

Magnetocardiography’s technical and clinical development had been primarily driven by Superconducting Quantum Interference Devices (SQUID). MCG hardware has evolved steadily from single channel laboratory-based investigational devices, to high-density commercially available units.


Genetesis is founded with the goal of catalyzing this science from the lab to enrich patient care.

Through always focusing on our end users and constantly scanning disciplines across science and technology, we are delivering powerful new tools to clinicians.

“We started working out of Thompson Library, the Summer of 2016. Every morning when we'd come in, we'd put a note on the window saying Yes We're Open, because we wanted to feel like a real business."

Peeyush Shrivastava, Co-Founder & CEO


This technological and clinical developmental process culminates in 2019 with the world’s first regulatory authorization [4]of an OPM-based MCG system for commercial sale: enter CardioFlux.

Genetesis receives FDA 510(k) clearance for its cardiac imaging platform. The platform pairs the CardioFlux™ Magnetocardiograph with the integrated Faraday Analytical Cloud™ (FAC).


FDA Awards Genetesis Breakthrough Device Designation for CardioFlux.

CardioFlux® is granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) for the diagnosis of myocardial ischemia and infarction in patients with symptoms suggestive of acute coronary syndrome.

"An important step forward for patients presenting to Emergency Departments across the country with acute chest pain. Chest pain risk stratification continues to be one of our most expensive, radiation intensive, and time-consuming diagnostic burdens in the Emergency Department."

Simon A. Mahler, MD, MS, FACEP


The ACCMED study begins enrollment across multiple Emergency Departments in the United States as one of the largest MCG studies to ever be performed.

Device is evaluated in a pilot clinical protocol studying the value of magnetocardiography in chest pain triage.


Genetesis Receives 2nd FDA Breakthrough Device Designation for Non-Invasive Diagnosis of Myocardial Ischemia.

The designation represents progress for patients with suspected Coronary Microvascular Dysfunction as the FDA recognizes disease’s debilitating impacts and the lack of effective non-invasive options for efficient diagnosis.

“This milestone is a great step forward for patients who suffer from the impacts of CMD, many of whom do so unknowingly, and illustrates the FDA’s awareness that effective CMD diagnostics are largely inaccessible to most patients."

Dr. Robert Takla, MD, MBA, FACEP

The values that
shape our team's work.

If you join the team, you’ll hear over and over how we operate from “first principles”. These values are what that really means.

Few problems in healthcare exist in a vacuum and even fewer still stand to be solved by a single individual. Building this company and its products will require overcoming seemingly impossible problems - problems we will overcome by relying on each other's individual strengths to generate joint success.
Success will require building trust with physicians who in turn are trusted by their very own patients. More than anything, trust is driven by boundless transparency. Inside Genetesis, a transparent culture means you'll always understand the context of your individual progress within the company's overall vision.
Executing our vision of empowering physicians and patients with the diagnostic certainty they need involves being empowered ourselves to be our best today... and even better tomorrow. Here, there's no such thing as a voice too small or idea too large. Voices are not just heard - they're listened to - and ideas are not just shared - they're acted upon.
Being able to work on a product that is going to materially impact people's lives - that's unbeatable. That's why, almost out of necessity, we want to work with others who are just as passionate as ourselves. After all, isn't it the passionate people who always end up pushing the boundaries of what's possible?

Our Founders

Meet the three founders who first saw the potential for MCG to change how patients experience cardiac care.

Peeyush Shrivastava

Co-Founder & CEO

Peeyush has 8 years of experience as a serial medical technology entrepreneur and technologist. He currently serves as the Co-Founder and Chief Executive Officer of Genetesis, where he has raised over $25 million in venture capital financing and led the company...

Vineet Erasala

Co-Founder & COO

Vineet is a proven product focused executive, specializing in full lifecycle medical device development and commercial access. As Co-Founder and Chief Operations Officer of Genetesis, he is highly adept at technical and corporate strategy implementation...

Manny Setegn

Co-Founder & CTO

Emmanuel is a highly technical co-founder and technical strategist with having had a background in software development and IT operation for nearly 10 years.  He currently serves as the Co-founder and Chief Technology Officer of Genetesis, where he has been responsible...

"We have made it our mission to to deliver the world’s most cost-effective and patient-centric solution for cardiovascular disease."

Peeyush Shrivastava

Co-Founder and CEO of Genetesis